CIDP Assessment Tools Infographic

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Assessment Tools
  • CIDP

A number of tools are available to assess disease severity and progression in patients with peripheral neuropathies such as CIDP. Gain a better understanding of four of these tools.

Featured Video

Dosing Schedules for IVIg: The Use of an Algorithm as a Suggestion for Personalized Dosing

Michael Lunn, PhD

National Hospital for Neurology and Neurosurgery, Queen Square, London

14:01 MIN
  • CIDP

Learn how an algorithm could be used to personalize dosing schedules for IVIg.

DOWNLOAD PDF

Our Experts

Peter Donofrio, MD
Vanderbilt University Medical Center, Nashville, TN, USA
Peter Donofrio, MD
Peter Donofrio, MD
Vanderbilt University Medical Center, Nashville, TN, USA
  • CIDP
  • GBS
Peter D. Donofrio, M.D. is a Professor of Neurology at Vanderbilt University Medical Center. He is a graduate of The Ohio State University School of Medicine and pursued a residency in neurology and a neuromuscular fellowship at the University of Michigan.
Michael Lunn, PhD

National Hospital for Neurology and Neurosurgery, Queen Square, London

Michael Lunn, PhD
Michael Lunn, PhD

National Hospital for Neurology and Neurosurgery, Queen Square, London

  • CIDP

Dr Michael Lunn is a Consultant Neurologist, Clinical Lead in Neuroimmunology and Honorary Senior Lecturer at the National Hospital for Neurology and Neurosurgery.

Nabil Moumane, MD
Medical Affairs and Pharmacology, CSL Behring
Nabil Moumane, MD
Nabil Moumane, MD
Medical Affairs and Pharmacology, CSL Behring
  • CIDP
  • MMN
Nabil Moumane is the Director of Medical Affairs and Pharmacology at CSL Behring.
David R. Cornblath, MD
Johns Hopkins University, Baltimore, MD, USA
David R. Cornblath, MD
David R. Cornblath, MD
Johns Hopkins University, Baltimore, MD, USA
  • GBS
David R. Cornblath received his MD from Case Western Reserve University and completed his residency and fellowship at the Hospital of the University of Pennsylvania under Prof. A.K. Asbury.
Back to Top